3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Neoplasms
2
Hematologic Neoplasms
2
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Breast Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
Cyclophosphamide
8
fludarabine
4
Rituximab
4
Melphalan
3
tetulomab tetraxetan lu-177
2
ponatinib
2
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Busulfan
2
Brentuximab Vedotin
2
Bortezomib
2
Bone Marrow Transplantation
2
trametinib
1
pertuzumab
1
penpulimab
1
pembrolizumab
1
ibritumomab tiuxetan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
cobimetinib
×
Lymphoid
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled